Suppression of melanoma-associated neoangiogenesis by bevacizumab

Archives of Dermatology
G JaissleP Szurman

Abstract

Bevacizumab, a potent antibody against the vascular endothelial growth factor (VEGF), has been shown to be effective for treatment of colorectal cancer. Recently, high effectiveness of bevacizumab in combination with paclitaxel has been reported in a single metastatic melanoma case. To our knowledge, we demonstrate for the first time the antiangiogenetic effect of bevacizumab in a patient with a vitreous melanoma metastasis. A 68-year-old man with a vitreous melanoma metastasis of the left eye was treated with a revitrectomy combined with intravitreal bevacizumab application because of iris neovascularization and progressive epiretinal tumor plaques. Four days after the treatment, the melanoma-associated neovascularization completely disappeared, but it recurred after 6 weeks. Although repetitive administration of local bevacizumab produced the same antiangiogenetic effect, progression of the epiretinal tumor plaques could not be stopped with the local bevacizumab treatment. Intraocular administration of the anti-VEGF drug bevacizumab causes immediate and complete regression of melanoma-associated angiogenesis. The rationale for the therapeutic strategy in our patient was an elevated level of VEGF in the vitreous cavity. Becaus...Continue Reading

Citations

May 12, 2010·American Journal of Clinical Oncology·Kristan D GuenterbergWilliam E Carson
May 9, 2009·Survey of Ophthalmology·Jonathan B Gunther, Michael M Altaweel
May 26, 2009·Hematology/oncology Clinics of North America·Alexander G Marneros
Dec 10, 2008·Expert Opinion on Therapeutic Targets·Luigi PasiniLuisa Lanfrancone
Dec 17, 2009·Expert Opinion on Pharmacotherapy·James PadsisDouglas Tyler
Apr 1, 2012·Retinal Cases & Brief Reports·Emilio Dorronzoro RamírezRosario García Vicuña
May 26, 2010·American Journal of Clinical Oncology·Joan Manel Gasent BlesaMariano Provencio Pulla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.